Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma Murali KesavanToby A. EyreGraham P. Collins B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor) Open access 29 June 2019 Pages: 207 - 218
Targeting Translation of mRNA as a Therapeutic Strategy in Cancer Ipsita PalMaryam SafariChangchun Deng B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor) 24 June 2019 Pages: 219 - 227
Considerations for the Treatment of Diffuse Large B Cell Lymphoma in the Elderly Yasir KhanElizabeth A. Brem B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor) 21 June 2019 Pages: 228 - 238
Mantle Cell Lymphoma: Which Patients Should We Transplant? James N. GersonStefan K. Barta B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor) 19 June 2019 Pages: 239 - 246
Pathogen-Specific T Cells Beyond CMV, EBV and Adenovirus Wei JiangBarbara WithersEmily Blyth CART and Immunotherapy (M Ruella and P Hanley, Section Editors) 21 June 2019 Pages: 247 - 260
Induced Pluripotent Stem Cell (iPSC)–Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges Alexandros NianiasMaria Themeli CART and Immunotherapy (M Ruella and P Hanley, Section Editors) Open access 26 June 2019 Pages: 261 - 268
Overcoming Challenges in Process Development of Cellular Therapies Steven L. HighfillDavid F. Stroncek CART and Immunotherapy (M Ruella and P Hanley, Section Editors) 06 July 2019 Pages: 269 - 277
Towards Automated Manufacturing for Cell Therapies David SmithThomas R. J. HeathmanBrian Hampson CART and Immunotherapy (M Ruella and P Hanley, Section Editors) 28 June 2019 Pages: 278 - 285
Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era Gerald P. LinetteBeatriz M. Carreno CART and Immunotherapy (M Ruella and P Hanley, Section Editors) 11 June 2019 Pages: 286 - 291
Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia Krish PatelJohn M. Pagel Chronic Lymphocytic Leukemias (N Jain, Section Editor) 15 June 2019 Pages: 292 - 301
Relevance of Prognostic Factors in the Era of Targeted Therapies in CLL Adam S. KittaiMatthew LunningAlexey V. Danilov Chronic Lymphocytic Leukemias (N Jain, Section Editor) 02 May 2019 Pages: 302 - 309
The Rationale for Immunotherapy in Myeloproliferative Neoplasms Lucia MasarovaPrithviraj BoseSrdan Verstovsek Myeloproliferative Neoplasms (B Stein, Section Editor) 21 June 2019 Pages: 310 - 327
Emerging Role of Integrative Medicine in Hematologic Malignancies: a Literature Review and Update on Current Trends in Complementary Medical Practices in Hematologic Cancers Onyemaechi N. OkoloKrisstina Gowin Health Economics (N Khera, Section Editor) 18 June 2019 Pages: 328 - 336
Is There a Role for Dose Modification of TKI Therapy in CML? M. Copland Chronic Myeloid Leukemias (M Mauro, Section Editor) Open access 14 June 2019 Pages: 337 - 345
Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS Rami S. Komrokji Myelodysplastic Syndromes (M Savona, Section Editor) 15 June 2019 Pages: 346 - 351